Zobrazeno 1 - 10
of 444
pro vyhledávání: ''
Autor:
William Novotny, Zhiyu Tang, Srikumar Sahasranaman, Ying C. Ou, Ta-Kai Li, Hugh A Coleman, Manal Tawashi
Publikováno v:
British Journal of Clinical Pharmacology
Aim This study aims to assess the potential effects of zanubrutinib on the activity of cytochrome P450 (CYP) enzymes and drug transporter proteins using a cocktail probe approach. Methods Patients received single oral doses of probe drugs alone and a
Autor:
Hiroshi Watanabe, Koichiro Tatsumi, Akio Hakamata, Naoki Katayama, Keiichi Odagiri, Naoki Inui, Noriyuki Namiki, Shimako Tanaka, Shinya Uchida, Chiaki Kamiya
Publikováno v:
British Journal of Clinical Pharmacology. 87:1903-1911
Aims The strong cytochrome P450 (CYP) 2C8 inhibitor gemfibrozil has been demonstrated to increase the area under the plasma concentration-time curve from 0 to infinity (AUC0-∞ ) of ACT-333679, an active metabolite of selexipag, by 11-fold. Similarl
Autor:
Victoria C. Ziesenitz, Alexandre N. Datta, Tatjana Welzel, Peter Weber, Verena Gotta, Johannes N. van den Anker
Publikováno v:
British Journal of Clinical Pharmacology. 87:1568-1573
Sodium channel 2 subunit α (SCN2A) mutations cause difficult-to-treat early-onset epilepsy. Effective treatment includes high-dose phenytoin or carbamazepine ± ketogenic diet (KD). We describe an infant with early-onset SCN2A-epilepsy with subthera
Autor:
Takafumi Nakatsu, Hitoshi Ishizuka, Takako Shimizu, Tomoko Ishizuka, Shin Irie, Manabu Kato, Hinako Uchimaru, Yasuhiro Nishikawa, Masanari Shiramoto, Yoshiaki Kirigaya
Publikováno v:
British Journal of Clinical Pharmacology
Aims To investigate the effects of the strong cytochrome P450 (CYP) 3A inhibitor itraconazole and the strong CYP3A inducer rifampicin on the pharmacokinetics of single-dose esaxerenone, a nonsteroidal mineralocorticoid receptor blocker, in healthy Ja
Autor:
Walter E. Haefeli, Gerd Mikus, Marlene Schaumaeker, Jürgen Burhenne, Marie-Louise Lehmann, Kathrin I. Foerster
Publikováno v:
British Journal of Clinical Pharmacology
Aims Using 3 different perpetrators the impact of voriconazole, cobicistat and rifampicin (single dose), we evaluated the suitability of a microdose cocktail of factor Xa inhibitors (FXaI; rivaroxaban, apixaban and edoxaban; 100 μg in total) to stud
Autor:
Helga Gardarsdottir, Patrick C. Souverein, Hendrika A. van den Ham, Yumao Zhang, Anthonius de Boer, Anke-Hilse Maitland-van der Zee
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 86(6), 1150. NLM (Medline)
British journal of clinical pharmacology, 86(6), 1150-1164. Wiley-Blackwell
British Journal of Clinical Pharmacology, 86(6), 1150. NLM (Medline)
British journal of clinical pharmacology, 86(6), 1150-1164. Wiley-Blackwell
Aims To assess the association between concurrent use of potential pharmacokinetic or pharmacodynamic interacting drugs and major bleeding among direct oral anticoagulant (DOAC) users. Methods We performed a case-control study nested in a cohort of n
Autor:
István Láng, Diane Wang, Chin-Hee Chung, Anna Plotka, Mohamed Elmeliegy, Elena A Smolyarchuk, Haihong Shi
Publikováno v:
British Journal of Clinical Pharmacology
Aims In vitro data show that talazoparib is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein transporters. This open-label, 2-arm, drug-drug interaction Phase 1 study in patients with advanced solid tumours assessed the effe
Autor:
Heli Malm, Maarit K. Leinonen, Anna-Maria Lahesmaa-Korpinen, Aleksi Tornio, Mikko Niemi, Maria Ellfolk
Publikováno v:
British Journal of Clinical Pharmacology
Aims P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are efflux transporters expressed in the placenta, limiting their substrates from reaching the foetus. Our aim was to investigate if concomitant prenatal exposure to several subst
Autor:
Hélène M. Faessel, Xiaofei Zhou, Karthik Venkatakrishnan, Douglas V. Faller, Farhad Sedarati, Diane R. Mould
Publikováno v:
British Journal of Clinical Pharmacology
Aims A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat PK. Methods Data were pooled from 6 clinical studies consisting of 335 patients with solid tumo
Publikováno v:
Br J Clin Pharmacol
Aims Chlorzoxazone is the paradigm marker substrate for CYP2E1 phenotyping in vivo. Because at the commonly used milligram doses (250-750 mg) chlorzoxazone acts as an inhibitor of the CYP3A4/5 marker substrate midazolam, previous attempts failed to c